Feature Channels: Pharmaceuticals

• share
• favorite_border

• share
• favorite_border

The proportion of people aged over 65 on antidepressants has more than doubled in two decades - according to new research led by the University of East Anglia.

• share
• favorite_border

• share
• favorite_border

A new scientific statement from the American Heart Association identifies the risks and benefits of using novel interventional devices compared to anticoagulation alone to treat patients with pulmonary embolism.

• share
• favorite_border

Mount Sinai researchers have discovered how the enzyme DNA polymerase delta works to duplicate the genome that cells hand down from one generation to the next.

• share
• favorite_border

Due to his innovations in the field of electrodiagnostic medicine, Dr. Buschbacher has been nominated for this year’s American Association of Neuromuscular and Electrodiagnostic Medicine (AANEM) Innovation Award.

• share
• favorite_border

Antidepressants are generally safe, according to a new study by an international team of researchers.

• share
• favorite_border

• share
• favorite_border

Aunque los estudios revelan que el tratamiento con medicamentos ayuda a la gente adicta a los opioides, poco se recurre a los tres fármacos autorizados por la Administración de Alimentos y Medicamentos de Estados Unidos, informa una revisión de los datos médicos actuales sobre la adicción a los opioides en Estados Unidos.

• share
• favorite_border

From a professional standpoint, Nathan Hoot, MD, PhD, understands the value of medical research that leads to new, groundbreaking drugs in the treatment of rare diseases. And as an emergency medicine physician, he’s familiar with adjusting ventilators and managing patients’ airways. But the magnitude of these matters also weigh on Hoot personally – as the father of a son with type 1 spinal muscular atrophy (SMA), a rare genetic disease that affects the part of the nervous system controlling voluntary muscle movement.

• share
• favorite_border

• share
• favorite_border

The national professional association for more than 50,000 nurse anesthesiologists was recognized by a global company for their innovative diversity and inclusion campaign.

• share
• favorite_border

The IU-led center is one of only two multi-institution teams in the nation selected as part of a new federal program intended to improve, diversify and reinvigorate the Alzheimer's disease drug development pipeline.

• share
• favorite_border

High value chemicals used to make pharmaceuticals could be made much cheaper and quicker thanks to a series of new catalysts made by scientists at the University of Warwick in collaboration with GoldenKeys High-Tech Co., Ltd. in China.

• share
• favorite_border

A UC Davis research team, led by Vladimir Yarov-Yarovoy and Heike Wulff, will receive a $1.5 million grant from the National Institutes of Health (NIH) to develop a novel class of peptides that are better at treating pain and don’t have the side effects of opioids. The grant is part of the NIH initiative Helping to End Addiction Long-Term (HEAL Initiative).

• share
• favorite_border

Argonne to become newest member of Accelerating Therapeutics for Opportunities in Medicine (ATOM) consortium.

• share
• favorite_border

Eighth annual SINAInnovations festival on October 15-16 at Icahn School of Medicine at Mount Sinai in New York City

• share
• favorite_border

Common herbs, including lavender, fennel and chamomile, have a long history of use as folk medicines used to lower blood pressure. In a new study, University of California, Irvine researchers explain the molecular mechanisms that make them work.

• share
• favorite_border

Researchers have solved the three-dimensional structure of a protein complex involved in vertebrate vision at atomic resolution, a finding that has broad implications for our understanding of biological signaling processes and the design of over a third of the drugs on the market today.

• share
• favorite_border

Researchers from the Institute of Neurosciences of the University of Barcelona (UBNeuro), Hospital Clínic and the August Pi i Sunyer Biomedical Research Institute (IDIBAPS) have identified a group of genetic variants related to the starting point of Parkinson's disease.

• share
• favorite_border

Cancer Research Institute analysis of the global immuno-oncology landscape shows dramatic two-year growth in therapeutic targets and I-O drugs in clinical development

• share
• favorite_border

Scientists from the UCLA Integrated Substance Abuse Programs will lead a $25 million National Institutes of Health study testing treatments, including the use of telemedicine, to help fight the opioid epidemic in rural America.

• share
• favorite_border

The Brain & Behavior Research Foundation today announced that William T. Carpenter, Jr., M.D., Professor of Psychiatry and Pharmacology at Maryland Psychiatric Research Center, Department of Psychiatry, the University of Maryland School of Medicine, is the recipient of the 2019 Pardes Humanitarian Prize in Mental Health.

• share
• favorite_border

Investigational drug with immunotherapy may provide new therapeutic opportunity for patients previously treated for kidney and lung cancer. Pegilodecakin with pembrolizumab and nivolumab shown to be safe in Phase IB study

• share
• favorite_border

A common tuberculosis (TB) vaccine could decrease the risk of lung cancer if administered during early childhood, according to a study published Sept. 25 in JAMA Network Online.

• share
• favorite_border

Benjamin S. Warfel, MD, was recently bestowed the 2019 American Association of Neuromuscular and Electrodiagnostic Medicine (AANEM) Advocacy Award. This award recognizes Dr. Warfel’s extraordinary contributions to increase public awareness and advocacy to government entities or insurance companies regarding the role of electrodiagnostic medicine in the diagnosis and treatment of disorders.

• share
• favorite_border

A collaboration between researchers from Cornell, Harvard, Stanford and the SLAC National Accelerator Laboratory has resulted in a reactive copper-nitrene catalyst that pries apart carbon-hydrogen (C–H) bonds and transforms them into carbon-nitrogen (C–N) bonds, which are a crucial building block for chemical synthesis, especially in pharmaceutical manufacturing.

• share
• favorite_border

One of the WHO’s three critical priority pathogens, Acinetobacter baumannii, for which new antibiotics are urgently needed is one step closer to being tackled, as researchers from the Department of Chemistry - University of Warwick have made a breakthrough in understanding the enzymes that assemble the antibiotic enacyloxin.

• share
• favorite_border

A new clinical trial conducted at The Ohio State University Wexner Medical Center found a cost-effective generic medication works just as well as a more expensive drug in preserving cardiovascular function in boys with Duchenne muscular dystrophy (DMD).

• share
• favorite_border

在一项小型安全性和可行性临床试验中，Mayo Clinic的研究人员首次证明，使用被称为“senolytic”的抗衰老药物可以清除人体内的衰老细胞。该结果不仅在血液分析中得到验证，而且在皮肤和脂肪组织衰老细胞丰度的变化中得到证实。研究结果发表在 EBioMedicine期刊上。

• share
• favorite_border

Em um ensaio clínico de segurança e viabilidade de pequena escala, pesquisadores da Mayo Clinic demonstraram pela primeira vez que células senescentes podem ser removidas do corpo por meio de medicamentos denominados "senolíticos". O resultado foi confirmado por análises sanguíneas e por alterações na abundância de células senescentes nos tecidos epitelial e adiposo. Os resultados foram publicados na revista EBioMedicine.

• share
• favorite_border

Dans le cadre d'un essai clinique d'innocuité et de faisabilité de faible portée, les chercheurs de la Mayo Clinic ont démontré pour la première fois que des médicaments qualifiés de « sénolytiques » pouvaient éliminer les cellules sénescentes de l'organisme. Le résultat a été vérifié non seulement dans les analyses sanguines, mais également dans les variations de quantités des cellules sénescentes de la peau et des tissus adipeux. Les résultats sont publiés dans la revue scientifique EBioMedicine.

• share
• favorite_border

In einer kleinen klinischen Sicherheits- und Machbarkeitsstudie haben Forscher der Mayo Clinic zum ersten Mal nachgewiesen, dass alternde Zellen mit Medikamenten, die als „Senolytika“ bezeichnet werden, aus dem menschlichen Körper entfernt werden können. Das Ergebnis wurde nicht nur in der Blutanalyse, sondern auch in der veränderten Menge seneszenter Zellen in Haut- und Fettgewebe bestätigt. Die Ergebnisse erscheinen in der Zeitschrift EBioMedicine.

• share
• favorite_border

Rutgers School of Dental Medicine (RSDM) was awarded an $11.7 million grant from the National Institutes of Health, (NIH) for research on the combination of ibuprofen and acetaminophen as an alternative to opioids.

• share
• favorite_border

A new approach to producing indolent scaffolds could streamline development and production of small-molecule pharmaceuticals, which comprise the majority of medicines in use today.

• share
• favorite_border

Skaggs School of Pharmacy and Pharmaceutical Sciences at University of California San Diego researchers describe new use of leukemia drug, nilotinib, to treat subtype of medulloblastoma, a deadly pediatric brain cancer.

• share
• favorite_border

A new study published today in Nature Communications shows a promising alternative for those who have to take a daily pill regimen.

• share
• favorite_border

IU scientists studying Medicare data have found an association between health care industry payments to medical providers for non-research expenses and what these providers charge for medical services.

• share
• favorite_border

• share
• favorite_border

Whitney Luke, MD, a board certified pain medicine and addiction medicine specialist at The Ohio State University Wexner Medical Center, explains how to properly taper opioid medication.

• share
• favorite_border

It takes about 10 years and $100 million to get a new medical device to market - $1 billion for a new drug. Most new solutions fail. The biggest foils are not the science or pre-clinical trials but the lack of finances, market miscalculation, bad business models, and regulatory snags. They can all be overcome.

• share
• favorite_border

En un pequeño ensayo clínico sobre seguridad y factibilidad, los investigadores de Mayo Clinic por vez primera demostraron que es posible extraer del cuerpo a las células senescentes con los fármacos llamados “senolíticos”. El resultado se verificó no solamente con análisis de sangre, sino también con el cambio en la abundancia de células senescentes en la piel y el tejido graso. Los resultados se publican en la revista EBioMedicine.

• share
• favorite_border

In companion presentations at the American Society for Therapeutic Radiation Oncology Annual Meeting, doctors from Roswell Park Comprehensive Cancer Center report new evidence that low-dose aspirin and other anti-inflammatories may improve survival in patients with some head/neck and lung cancers.

• share
• favorite_border

A technology that manipulates microRNAs (miRNAs) developed by Jingfang Ju, PhD, a biochemist and Professor in the Department of Pathology at the Renaissance School of Medicine at Stony Brook University, and colleagues has shown promise when used as anti-cancer therapeutic.

• share
• favorite_border

NUS researchers have developed a new anti-cancer drug that have less toxic effects to the kidneys. It works like a ‘magic bullet’ that is delivered directly to the mitochondria. Such targeted approach reduces the drug’s interactions with other tissues, minimising side effects and lower the risk of patients developing resistance to anti-cancer drugs.

• share
• favorite_border

Proteins keep our organs functioning, egulate our cells and are the targets for medications that treat a number of diseases, including cancers and neurological diseases. Proteins need to move in order to function. But, because the technology they used to watch proteins doesn't allow it, scientists still know very little about such motions at speeds slower than a nanosecond.

• share
• favorite_border

Researchers at the University of Helsinki in collaboration with researchers from Åbo Akademi University,Finland and Huazhong University of Science and Technology,China have developed a new anti-cancer nanomedicine for targeted cancer chemotherapy.